Mast Therapeutics (MSTX) Tops Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Mast Therapeutics Reports Second Quarter 2016 Financial Results
August 9, 2016 8:01 AM EDTSAN DIEGO, Aug. 9, 2016 /PRNewswire/ --Â Mast Therapeutics, Inc. (NYSE MKT: MSTX), a biopharmaceutical company developing novel, clinical-stage therapies for sickle cell disease and heart failure, today reported financial results for the quarter ended June 30, 2016.
"We continued to advance our assets toward valuable inflection points during the second quarter. Announcing top-line data from the EPIC study continues to be our top priority. With 388 subjects randomized at study sites around the globe, EPIC was the largest... More
Mast Therapeutics Awarded Small Business Innovation Research Grant From The National Institutes Of Health
August 8, 2016 8:00 AM EDTSAN DIEGO, Aug. 8, 2016 /PRNewswire/ -- Mast Therapeutics, Inc. (NYSE MKT: MSTX), a biopharmaceutical company developing novel, clinical-stage therapies for sickle cell disease and heart failure, today reported that it received a Small Business Innovation Research (SBIR) grant from the National Institute Of Neurological Disorders And Stroke (NINDS) of the National Institutes of Health (NIH). The grant will support investigation of the Company's lead product candidate, vepoloxamer, in combination with tissue plasminogen activator (tPA) in experimental models of... More
